I'll believe FDA approval when I see it.
Compass may hold off on any significant deal until MEB need to CR.
Then Compass could say, Make it an institutional raise and we will buy the entire CR.
Then all of a sudden, Compass will roll out Ilumen big time and the big guy wins.
Just a scenario and all IMO.
I certainly hope they are a friend and not underhanded.
Ann: FDA Strategy and Regulatory Update, page-590
-
- There are more pages in this discussion • 103 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
